| 0.1845 0.008 (4.24%) | 12-08 12:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.26  |
1-year : | 0.31 |
| Resists | First : | 0.23 |
Second : | 0.26 |
| Pivot price | 0.16  |
|||
| Supports | First : | 0.15 |
Second : | 0.11 |
| MAs | MA(5) : | 0.18 |
MA(20) : | 0.17 |
| MA(100) : | 0.38 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.4 |
D(3) : | 67.8 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 2.4 | Low : | 0.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PFSA ] has closed below upper band by 15.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.18 - 0.18 | 0.18 - 0.19 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.18 - 0.18 | 0.18 - 0.18 |
A digital-health company developing tissue-integrating biosensors (e.g.
Thu, 04 Dec 2025
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Wed, 19 Nov 2025
Profusa, Inc. SEC 10-Q Report - TradingView
Wed, 17 Sep 2025
Profusa receives Nasdaq notices for minimum value and bid price compliance - Investing.com
Tue, 26 Aug 2025
Profusa amends purchase agreement and note terms for convertible debt tranches - Investing.com
Wed, 06 Aug 2025
Profusa, Inc. Outlines Growth Strategy and Milestones in Shareholder Letter Following Nasdaq Listing - Quiver Quantitative
Mon, 21 Jul 2025
Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Equipment & Services
|
|
| Shares Out | 66 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 2,080 (K) |
| Shares Short P.Month | 1,020 (K) |
| EPS | -0.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.82 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -465.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | -0.24 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|